GlassScriptPhysician profile
Weiming R Yan
NPI 1851552624
$7,458.97
in general payments reported to CMS, 2019-2025
30 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $82.60 · 2021: $303 · 2022: $1,452 · 2023: $1,873 · 2024: $1,865 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,150 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,150.22 |
| Education | $198.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,328.89 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,196.20 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $941.53 | 2021-2025 | Trulance, Xifaxan, Relistor |
| Janssen Biotech, INC. | $569.17 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $524.34 | 2021-2024 | Zeposia |
| Pfizer INC. | $375.36 | 2022-2025 | |
| Gilead Sciences, INC. | $323.82 | 2021-2024 | Vemlidy |
| Ardelyx, INC. | $208.90 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $158.19 | 2022-2024 | Injectafer |
| Lilly USA, LLC | $157.19 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $155.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $154.26 | 2021-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $149.40 | 2024-2025 | Voquezna |
| Fresenius Kabi USA, LLC | $135.53 | 2023-2024 | Idacio |
| Nestle Healthcare Nutrition INC. | $112.22 | 2021-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $108.29 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $103.37 | 2019 | |
| Ferring Pharmaceuticals INC. | $102.84 | 2023 | Rebyota |
| Ars Pharmaceuticals Operations, INC. | $100.00 | 2025 | Neffy |
| Angiodynamics, INC. | $95.23 | 2024 | Nanoknife |
| Boston Scientific Corporation | $88.33 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $87.05 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $87.04 | 2022-2024 | Linzess |
| Amgen INC. | $60.11 | 2023 | Avsola, Amjevita |
| Ipsen Biopharmaceuticals, INC | $37.73 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $30.11 | 2022-2023 | Zinplava, Dificid |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Shionogi INC | $19.52 | 2020 | |
| Organon LLC | $18.34 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weiming Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.